Trials Sponsors Conditions Drugs Pricing

Conditions

Myelofibrosis

Outcome Measures

Primary Outcomes (1)

Overall survival according to the presence of cytopenias at diagnosis
Obtained by medical health records normally filled out in clinical practice
At diagnosis during the baseline

Secondary Outcomes (8)

Frequency and types of cytopenias
At baseline; 1 year follow-up.
Treatments response and duration (according to modified IWG-MRT and ELN 2013 criteria, overall and by presence of cytopenias
At baseline; 1 year follow-up.
Incidence of major CV events (thrombosis and bleeding), overall and by presence of cytopenias and treatments received
At baseline; 1 year follow-up.
Incidence of disease progressions (MF accelerated phase, MF blast phase/acute myeloid leukemia (AML)), overall and by presence of cytopenias and treatments received
At baseline; 1 year follow-up.
Incidence of secondary neoplasia, overall, by site and by presence of cytopenias and treatments received
At baseline; 1 year follow-up.
+3 more secondary outcomes

Eligibility Criteria

Age18 Years - 100 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Patients with a 2016- or 2022-WHO confirmed diagnosis of MF established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Patients with primary and secondary to ET and PV myelofibrosis, annotated for genetic and histological features, in relation to the presence of baseline (i.e., at MF diagnosis) or treatment-related cytopenias (i.e., reduced count of blood cells manifesting as anemia, thrombocytopenia and/or neutropenia).

You may qualify if:

Sponsors & Collaborators

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Otherlead
GlaxoSmithKline
Industrycollaborator

Study Sites (27)

Hematology Center after Prof.R.H. Yeolyan

Yerevan, Armenia

RECRUITING

CONTACTbadikyanmaria@gmail.com

Maria Badikyan, MDPRINCIPAL INVESTIGATOR

University Hospital Halle Department of Hematology/Oncology

Halle, Germany

NOT_YET_RECRUITING

CONTACThaifa.al-ali@uk-halle.de

MeSH Terms

Conditions

Primary Myelofibrosis

Condition Hierarchy (Ancestors)

Myeloproliferative DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic Diseases

Study Officials

TIZIANO BARBUI, MD
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
STUDY DIRECTOR

Central Study Contacts

TIZIANO BARBUI, MD

CONTACT

0352675134 tbarbui@fondazionefrom.it

FENILI

CONTACT

sperimentazioni@fondazionefrom.it

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

July 19, 2024

First Posted

August 1, 2024

Study Start

October 14, 2024

Actual (reported)

Primary Completion

December 31, 2028

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (27)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (27)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations